NanoViricides, Inc. (NYSE American: NNVC) announced that it has shipped NV-387 Oral Gummies to the Democratic Republic of Congo (DRC) in preparation for a Phase II clinical trial evaluating the drug as a treatment for MPox. The company stated that site preparations are being conducted by its contract research organization, Om Sai Clinical Research Pvt. Ltd., and local partners, with patient enrollment and dosing expected to begin following completion of staff training in the coming weeks.
The trial will assess the safety and effectiveness of NV-387 in patients with MPox caused by human monkeypox virus infection, primarily the more severe Clade I strain endemic to the DRC. NanoViricides noted that NV-387, a broad-spectrum antiviral candidate, has also been proposed for evaluation against Ebola virus infections. The shipment makes the drug locally available should it be utilized in response efforts. Successful clinical development of NV-387 could position the therapy as a potential treatment option for multiple viral diseases, including MPox and Ebola.
NanoViricides is a clinical stage company creating special purpose nanomaterials for antiviral therapy. Its lead drug candidate, NV-387, is a broad-spectrum antiviral drug planned for development as a treatment for RSV, COVID, Long COVID, Influenza, other respiratory viral infections, as well as MPOX/Smallpox infections and Measles. The company's other advanced drug candidate is NV-HHV-1 for the treatment of Shingles. NanoViricides is currently focused on advancing NV-387 into Phase II human clinical trials.
The company also develops drugs against a number of viral diseases including oral and genital Herpes, viral diseases of the eye including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal Influenza, HIV, Hepatitis C, Rabies, Dengue fever, and Ebola virus, among others. NanoViricides' platform technology and programs are based on the TheraCour nanomedicine technology of TheraCour, which TheraCour licenses from AllExcel. The company holds a worldwide exclusive perpetual license to this technology for several drugs with specific targeting mechanisms for the treatment of various human viral diseases.
As with any drug development efforts, there can be no assurance that any of the company's pharmaceutical candidates would show sufficient effectiveness and safety for human clinical development. Further, there can be no assurance that successful results against coronavirus in the lab will lead to successful clinical trials or a successful pharmaceutical product.
For more information, visit the company's newsroom at https://ibn.fm/NNVC.
